Skip to main content
SpringerLink
Log in

Bullous Pemphigoid

  • Chapter
  • First Online:
Autoimmune Bullous Diseases

Abstract

Bullous pemphigoid is the most common cutaneous autoimmune blistering diseases with an estimated incidence in the United States of 24 cases per million person-years. It is a chronic disease of the elderly that can cause significant morbidity secondary to pruritus and open wounds. High potency topical corticosteroids are effective for patients with limited disease and in treating disease flares. Oral corticosteroids are the main stay of early treatment for more extensive disease because of their fast onset of action, but should not be used for long-term management at high doses because of the significant risk of potentially serious side effects. Steroid-sparing agents such as azathioprine, mycophenolate mofetil and methotrexate have shown to be effective in decreasing the dose of systemic corticosteroids required. For more recalcitrant cases, IVIG and rituximab can also be considered. The choice of an appropriate treatment must also balance the risks of systemic immunosuppression in this elderly population with other medical comorbidities.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 119.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Abbreviations

ABD:

Autoimmune bullous disease

BP:

Bullous pemphigoid

BSA:

Body surface area

IF:

Immunofluorescence

IVIG:

Intravenous immunoglobulin

mg/m2:

milligrams per square meter

References

  1. Bernard P, Borradori L. Pemphigoid group. In: Bolognia J, Jorizzo J, Rapini R, editors. Dermatology (Basel, Switzerland). 3rd ed. Philadelphia: Elsevier; 2012. p. 475–90.

    Google Scholar 

  2. Bernard P, Vaillant L, Labeille B, Bedane C, Arbeille B, Denoeux JP, et al. Incidence and distribution of subepidermal autoimmune bullous skin diseases in three French regions. Bullous Diseases French Study Group. Arch Dermatol. 1995;131(1):48–52.

    Article  CAS  PubMed  Google Scholar 

  3. Zillikens D, Wever S, Roth A, Weidenthaler-Barth B, Hashimoto T, Brocker EB. Incidence of autoimmune subepidermal blistering dermatoses in a region of central Germany. Arch Dermatol. 1995;131(8):957–8.

    Article  CAS  PubMed  Google Scholar 

  4. Joly P, Baricault S, Sparsa A, Bernard P, Bedane C, Duvert-Lehembre S, et al. Incidence and mortality of bullous pemphigoid in France. J Invest Dermatol. 2012;132(8):1998–2004.

    Article  CAS  PubMed  Google Scholar 

  5. Langan SM, Smeeth L, Hubbard R, Fleming KM, Smith CJ, West J. Bullous pemphigoid and pemphigus vulgaris--incidence and mortality in the UK: population based cohort study. BMJ (Clin Res Ed). 2008;337:a180.

    Article  CAS  Google Scholar 

  6. Bertram F, Brocker EB, Zillikens D, Schmidt E. Prospective analysis of the incidence of autoimmune bullous disorders in Lower Franconia, Germany. J Dtsch Dermatol Ges. 2009;7(5):434–40.

    PubMed  Google Scholar 

  7. Brick KE, Weaver CH, Lohse CM, Pittelkow MR, Lehman JS, Camilleri MJ, et al. Incidence of bullous pemphigoid and mortality of patients with bullous pemphigoid in Olmsted County, Minnesota, 1960 through 2009. J Am Acad Dermatol. 2014;71(1):92–9.

    Article  PubMed Central  PubMed  Google Scholar 

  8. Jung M, Kippes W, Messer G, Zillikens D, Rzany B. Increased risk of bullous pemphigoid in male and very old patients: a population-based study on incidence. J Am Acad Dermatol. 1999;41(2 Pt 1):266–8.

    Article  CAS  PubMed  Google Scholar 

  9. Parker SR, Dyson S, Brisman S, Pennie M, Swerlick RA, Khan R, et al. Mortality of bullous pemphigoid: an evaluation of 223 patients and comparison with the mortality in the general population in the United States. J Am Acad Dermatol. 2008;59(4):582–8.

    Article  PubMed  Google Scholar 

  10. Colbert RL, Allen DM, Eastwood D, Fairley JA. Mortality rate of bullous pemphigoid in a US medical center. J Invest Dermatol. 2004;122(5):1091–5.

    Article  CAS  PubMed  Google Scholar 

  11. Kirtschig G, Middleton P, Bennett C, Murrell DF, Wojnarowska F, Khumalo NP. Interventions for bullous pemphigoid. Cochrane Database Syst Rev. 2010(10):CD002292.

    Google Scholar 

  12. Joly P, Roujeau JC, Benichou J, Picard C, Dreno B, Delaporte E, et al. A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N Engl J Med. 2002;346(5):321–7.

    Article  CAS  PubMed  Google Scholar 

  13. Joly P, Roujeau JC, Benichou J, Delaporte E, D’Incan M, Dreno B, et al. A comparison of two regimens of topical corticosteroids in the treatment of patients with bullous pemphigoid: a multicenter randomized study. J Invest Dermatol. 2009;129(7):1681–7.

    Article  CAS  PubMed  Google Scholar 

  14. Ingen-Housz-Oro S, Valeyrie-Allanore L, Ortonne N, Roujeau JC, Wolkenstein P, Chosidow O. Management of bullous pemphigoid with topical steroids in the clinical practice of a single center: outcome at 6 and 12 months. Dermatol (Basel Switzerland). 2011;222(2):176–9.

    Article  CAS  Google Scholar 

  15. Westerhof W. Treatment of bullous pemphigoid with topical clobetasol propionate. J Am Acad Dermatol. 1989;20(3):458–61.

    Article  CAS  PubMed  Google Scholar 

  16. Chu J, Bradley M, Marinkovich MP. Topical tacrolimus is a useful adjunctive therapy for bullous pemphigoid. Arch Dermatol. 2003;139(6):813–5.

    Article  PubMed  Google Scholar 

  17. Morel P, Guillaume JC. Treatment of bullous pemphigoid with prednisolone only: 0.75 mg/kg/day versus 1.25 mg/kg/day. A multicenter randomized study. Ann Dermatol Venereol. 1984;111(10):925–8.

    CAS  PubMed  Google Scholar 

  18. Dreno B, Sassolas B, Lacour P, Montpoint S, Lota I, Giordano F, et al. Methylprednisolone versus prednisolone methylsulfobenzoate in pemphigoid: a comparative multicenter study. Ann Dermatol Venereol. 1993;120(8):518–21.

    CAS  PubMed  Google Scholar 

  19. Chosidow O, Saada V, Diquet B, Roujeau JC, Revuz J. Correlation between the pretreatment number of blisters and the time to control bullous pemphigoid with prednisone 1 mg/kg/day. Br J Dermatol. 1992;127(2):185–6.

    Article  CAS  PubMed  Google Scholar 

  20. Loo WJ, Kirtschig G, Wojnarowska F. Minocycline as a therapeutic option in bullous pemphigoid. Clin Exp Dermatol. 2001;26(5):376–9.

    Article  CAS  PubMed  Google Scholar 

  21. Thornfeldt CR, Menkes AW. Bullous pemphigoid controlled by tetracycline. J Am Acad Dermatol. 1987;16(2 Pt 1):305–10.

    Article  CAS  PubMed  Google Scholar 

  22. Altomare G, Capella GL, Fracchiolla C, Frigerio E. Treatment of bullous pemphigoid with erythromycin: a reappraisal. Eur J Dermatol. 1999;9(7):583–5.

    CAS  PubMed  Google Scholar 

  23. Fivenson DP, Breneman DL, Rosen GB, Hersh CS, Cardone S, Mutasim D. Nicotinamide and tetracycline therapy of bullous pemphigoid. Arch Dermatol. 1994;130(6):753–8.

    Article  CAS  PubMed  Google Scholar 

  24. Berk MA, Lorincz AL. The treatment of bullous pemphigoid with tetracycline and niacinamide. A preliminary report. Arch Dermatol. 1986;122(6):670–4.

    Article  CAS  PubMed  Google Scholar 

  25. Kolbach DN, Remme JJ, Bos WH, Jonkman MF, De Jong MC, Pas HH, et al. Bullous pemphigoid successfully controlled by tetracycline and nicotinamide. Br J Dermatol. 1995;133(1):88–90.

    Article  CAS  PubMed  Google Scholar 

  26. Shiohara J, Yoshida K, Hasegawa J, Uhara H, Takata M, Saida T, et al. Tetracycline and niacinamide control bullous pemphigoid but not pemphigus foliaceus when these conditions coexist. J Dermatol. 2010;37(7):657–61.

    Article  PubMed  Google Scholar 

  27. Honl BA, Elston DM. Autoimmune bullous eruption localized to a breast reconstruction site: response to niacinamide. Cutis. 1998;62(2):85–6.

    CAS  PubMed  Google Scholar 

  28. Venning VA, Millard PR, Wojnarowska F. Dapsone as first line therapy for bullous pemphigoid. Br J Dermatol. 1989;120(1):83–92.

    Article  CAS  PubMed  Google Scholar 

  29. Bouscarat F, Chosidow O, Picard-Dahan C, Sakiz V, Crickx B, Prost C, et al. Treatment of bullous pemphigoid with dapsone: retrospective study of thirty-six cases. J Am Acad Dermatol. 1996;34(4):683–4.

    Article  CAS  PubMed  Google Scholar 

  30. Jeffes 3rd EW, Ahmed AR. Adjuvant therapy of bullous pemphigoid with dapsone. Clin Exp Dermatol. 1989;14(2):132–6.

    Article  PubMed  Google Scholar 

  31. Guillaume JC, Vaillant L, Bernard P, Picard C, Prost C, Labeille B, et al. Controlled trial of azathioprine and plasma exchange in addition to prednisolone in the treatment of bullous pemphigoid. Arch Dermatol. 1993;129(1):49–53.

    Article  CAS  PubMed  Google Scholar 

  32. Burton JL, Harman RR, Peachey RD, Warin RP. Azathioprine plus prednisone in treatment of pemphigoid. Br Med J. 1978;2(6146):1190–1.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  33. Beissert S, Werfel T, Frieling U, Bohm M, Sticherling M, Stadler R, et al. A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of bullous pemphigoid. Arch Dermatol. 2007;143(12):1536–42.

    Article  CAS  PubMed  Google Scholar 

  34. Ahmed AR, Maize JC, Provost TT. Bullous pemphigoid. Clinical and immunologic follow-up after successful therapy. Arch Dermatol. 1977;113(8):1043–6.

    Article  CAS  PubMed  Google Scholar 

  35. Greaves MW, Burton JL, Marks J, Dawber RP. Azathioprine in treatment of bullous pemphigoid. Br Med J. 1971;1(5741):144–5.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  36. Burton JL, Greaves MW. Azathioprine for pemphigus and pemphigoid – a 4 year follow-up. Br J Dermatol. 1974;91(1):103–9.

    Article  CAS  PubMed  Google Scholar 

  37. van Dijk TJ, van Velde JL. Treatment of pemphigus and pemphigoid with azathioprine. Dermatologica. 1973;147(3):179–85.

    Article  PubMed  Google Scholar 

  38. Schram ME, Borgonjen RJ, Bik CM, van der Schroeff JG, van Everdingen JJ, Spuls PI. Off-label use of azathioprine in dermatology: a systematic review. Arch Dermatol. 2011;147(4):474–88.

    Article  PubMed  Google Scholar 

  39. Gunay U, Gunduz K, Ermertcan AT, Kandiloglu AR. Coexistence of psoriasis and bullous pemphigoid: remission with low-dose methotrexate. Cutan Ocul Toxicol. 2013;32(2):168–9.

    Article  PubMed  Google Scholar 

  40. Bara C, Maillard H, Briand N, Celerier P. Methotrexate for bullous pemphigoid: preliminary study. Arch Dermatol. 2003;139(11):1506–7.

    Article  PubMed  Google Scholar 

  41. Dereure O, Bessis D, Guillot B, Guilhou JJ. Treatment of bullous pemphigoid by low-dose methotrexate associated with short-term potent topical steroids: an open prospective study of 18 cases. Arch Dermatol. 2002;138(9):1255–6.

    Article  PubMed  Google Scholar 

  42. Heilborn JD, Stahle-Backdahl M, Albertioni F, Vassilaki I, Peterson C, Stephansson E. Low-dose oral pulse methotrexate as monotherapy in elderly patients with bullous pemphigoid. J Am Acad Dermatol. 1999;40(5 Pt 1):741–9.

    Article  CAS  PubMed  Google Scholar 

  43. Bohm I, Bauer R. Treatment of bullous pemphigoid with low-dose methotrexate. Der Hautarzt Zeitschrift fur Dermatologie Venerologie und verwandte Gebiete. 1997;48(12):910–4.

    Article  CAS  Google Scholar 

  44. Paul MA, Jorizzo JL, Fleischer Jr AB, White WL. Low-dose methotrexate treatment in elderly patients with bullous pemphigoid. J Am Acad Dermatol. 1994;31(4):620–5.

    Article  CAS  PubMed  Google Scholar 

  45. Kjellman P, Eriksson H, Berg P. A retrospective analysis of patients with bullous pemphigoid treated with methotrexate. Arch Dermatol. 2008;144(5):612–6.

    Article  CAS  PubMed  Google Scholar 

  46. Bohm M, Beissert S, Schwarz T, Metze D, Luger T. Bullous pemphigoid treated with mycophenolate mofetil. Lancet. 1997;349(9051):541.

    Article  CAS  PubMed  Google Scholar 

  47. Nousari HC, Griffin WA, Anhalt GJ. Successful therapy for bullous pemphigoid with mycophenolate mofetil. J Am Acad Dermatol. 1998;39(3):497–8.

    Article  CAS  PubMed  Google Scholar 

  48. Grundmann-Kollmann M, Korting HC, Behrens S, Kaskel P, Leiter U, Krahn G, et al. Mycophenolate mofetil: a new therapeutic option in the treatment of blistering autoimmune diseases. J Am Acad Dermatol. 1999;40(6 Pt 1):957–60.

    Article  CAS  PubMed  Google Scholar 

  49. Barthelemy H, Thivolet J, Cambazard F, Bendelac A, Mauduit G, Granier F, et al. Cyclosporin in the treatment of bullous pemphigoid: preliminary study. Ann Dermatol Venereol. 1986;113(4):309–13.

    CAS  PubMed  Google Scholar 

  50. Thivolet J, Barthelemy H, Rigot-Muller G, Bendelac A. Effects of cyclosporin on bullous pemphigoid and pemphigus. Lancet. 1985;1(8424):334–5.

    Article  CAS  PubMed  Google Scholar 

  51. Roujeau JC, Revuz J, Touraine R, Joneau-Fabre M, Mannoni P. Cortico-resistant bullous pemphigoid. Favorable results with plasmapheresis. Nouv Presse Med. 1979;8(41):3362.

    CAS  PubMed  Google Scholar 

  52. Guillaume JC, Roujeau JC, Touzet C, Revuz J, Touraine R. [Treatment of bullous pemphigoid by plasma exchange and prednisolone]. Presse Med (Paris France: 1983). 1985;14(20):1139–42.

    CAS  Google Scholar 

  53. Roujeau JC, Guillaume JC, Morel P, Crickx B, Dalle E, Doutre MS, et al. Plasma exchange in bullous pemphigoid. Lancet. 1984;2(8401):486–8.

    Article  CAS  PubMed  Google Scholar 

  54. Yamada H, Yaguchi H, Takamori K, Ogawa H. Plasmapheresis for the treatment of pemphigus vulgaris and bullous pemphigoid. Therap A. 1997;1(2):178–82.

    Article  CAS  Google Scholar 

  55. Egan CA, Meadows KP, Zone JJ. Plasmapheresis as a steroid saving procedure in bullous pemphigoid. Int J Dermatol. 2000;39(3):230–5.

    Article  CAS  PubMed  Google Scholar 

  56. Mazzi G, Raineri A, Zanolli FA, Da Ponte C, De Roia D, Santarossa L, et al. Plasmapheresis therapy in pemphigus vulgaris and bullous pemphigoid. Transfus A Sci. 2003;28(1):13–8.

    Article  Google Scholar 

  57. Chang B, Tholpady A, Huang RS, Nedelcu E, Bai Y. Clinical and serological responses following plasmapheresis in bullous pemphigoid: two case reports and a review of the literature. Blood Transfus. 2014;12(2):269–75.

    PubMed Central  PubMed  Google Scholar 

  58. Kitabata Y, Sakurane M, Orita H, Kamimura M, Siizaki K, Narukawa N, et al. Double filtration plasmapheresis for the treatment of bullous pemphigoid: a three case report. Ther A. 2001;5(6):484–90.

    CAS  Google Scholar 

  59. Lee MW, Lee WS, Choi JH, Sung KJ, Moon KC, Koh JK. A case of severe bullous pemphigoid treated with plasmapheresis. J Dermatolog Treat. 2001;12(1):59–60.

    Article  CAS  PubMed  Google Scholar 

  60. Konstadt JW, Remlinger K, Schild J, Aronson I, Bennin B, Solomon L. Refractory bullous pemphigoid leading to respiratory arrest and successfully treated with plasmapheresis. Arch Dermatol. 1990;126(9):1241–2.

    Article  CAS  PubMed  Google Scholar 

  61. Guillot B, Donadio D, Guilhou JJ, Meynadier J. Long term plasma exchange therapy in bullous pemphigoid. Acta Derm Venereol. 1986;66(1):73–5.

    CAS  PubMed  Google Scholar 

  62. Muller PA, Brocker EB, Klinker E, Stoevesandt J, Benoit S. Adjuvant treatment of recalcitrant bullous pemphigoid with immunoadsorption. Dermatol (Basel Switzerland). 2012;224(3):224–7.

    Article  CAS  Google Scholar 

  63. Godard W, Roujeau JC, Guillot B, Andre C, Rifle G. Bullous pemphigoid and intravenous gammaglobulin. Ann Int Med. 1985;103(6 (Pt 1)):964–5.

    CAS  PubMed  Google Scholar 

  64. Ahmed AR. Intravenous immunoglobulin therapy for patients with bullous pemphigoid unresponsive to conventional immunosuppressive treatment. J Am Acad Dermatol. 2001;45(6):825–35.

    Article  CAS  PubMed  Google Scholar 

  65. Sami N, Ali S, Bhol KC, Ahmed AR. Influence of intravenous immunoglobulin therapy on autoantibody titres to BP Ag1 and BP Ag2 in patients with bullous pemphigoid. J Eur Acad Dermatol Venereo. 2003;17(6):641–5.

    Article  CAS  Google Scholar 

  66. Lourari S, Herve C, Doffoel-Hantz V, Meyer N, Bulai-Livideanu C, Viraben R, et al. Bullous and mucous membrane pemphigoid show a mixed response to rituximab: experience in seven patients. J Eur Acad Dermatol Venereo. 2011;25(10):1238–40.

    Article  CAS  Google Scholar 

  67. Hall 3rd RP, Streilein RD, Hannah DL, McNair PD, Fairley JA, Ronaghy A, et al. Association of serum B-cell activating factor level and proportion of memory and transitional B cells with clinical response after rituximab treatment of bullous pemphigoid patients. J Invest Dermatol. 2013;133(12):2786–8.

    Article  CAS  PubMed  Google Scholar 

  68. Saouli Z, Papadopoulos A, Kaiafa G, Girtovitis F, Kontoninas Z. A new approach on bullous pemphigoid therapy. Ann Oncol. 2008;19(4):825–6.

    Article  CAS  PubMed  Google Scholar 

  69. Reguiai Z, Tchen T, Perceau G, Bernard P. Efficacy of rituximab in a case of refractory bullous pemphigoid. Ann Dermatol Venereol. 2009;136(5):431–4.

    Article  CAS  PubMed  Google Scholar 

  70. Saraceno R, Citarella L, Spallone G, Chimenti S. A biological approach in a patient with psoriasis and bullous pemphigoid associated with losartan therapy. Clin Exp Dermatol. 2008;33(2):154–5.

    Article  CAS  PubMed  Google Scholar 

  71. Kasperkiewicz M, Shimanovich I, Ludwig RJ, Rose C, Zillikens D, Schmidt E. Rituximab for treatment-refractory pemphigus and pemphigoid: a case series of 17 patients. J Am Acad Dermatol. 2011;65(3):552–8.

    Article  CAS  PubMed  Google Scholar 

  72. Wang TS, Tsai TF. Remission of bullous pemphigoid after rituximab treatment in a psoriasis patient on regular low-dose methotrexate. Acta Derm Venereol. 2014;94(1):108–9.

    Article  PubMed  Google Scholar 

  73. Schmidt E, Seitz CS, Benoit S, Brocker EB, Goebeler M. Rituximab in autoimmune bullous diseases: mixed responses and adverse effects. Br J Dermatol. 2007;156(2):352–6.

    Article  CAS  PubMed  Google Scholar 

  74. Taieb A, Klene C, Maleville J. Immediate treatment of bullous pemphigus with a corticosteroid-cyclophosphamide combination. Ann Dermatol Venereol. 1986;113(12):1223–9.

    CAS  PubMed  Google Scholar 

  75. Gual A, Iranzo P, Mascaro Jr JM. Treatment of bullous pemphigoid with low-dose oral cyclophosphamide: a case series of 20 patients. J Eur Acad Dermatol Venereo. 2014;28(6):814–8.

    Article  CAS  Google Scholar 

  76. Dawe RS, Naidoo DK, Ferguson J. Severe bullous pemphigoid responsive to pulsed intravenous dexamethasone and oral cyclophosphamide. Br J Dermatol. 1997;137(5):826–7.

    Article  CAS  PubMed  Google Scholar 

  77. Yu KK, Crew AB, Messingham KA, Fairley JA, Woodley DT. Omalizumab therapy for bullous pemphigoid. J Am Acad Dermatol. 2014;71(3):468–74.

    Article  CAS  PubMed  Google Scholar 

  78. Dufour C, Souillet AL, Chaneliere C, Jouen F, Bodemer C, Jullien D, et al. Successful management of severe infant bullous pemphigoid with omalizumab. Br J Dermatol. 2012;166(5):1140–2.

    Article  CAS  PubMed  Google Scholar 

  79. Yalcin AD, Genc GE, Celik B, Gumuslu S. Anti-IgE monoclonal antibody (omalizumab) is effective in treating bullous pemphigoid and its effects on soluble CD200. Clin Lab. 2014;60(3):523–4.

    PubMed  Google Scholar 

  80. Murrell DF, Daniel BS, Joly P, Borradori L, Amagai M, Hashimoto T, et al. Definitions and outcome measures for bullous pemphigoid: recommendations by an international panel of experts. J Am Acad Dermatol. 2012;66(3):479–85.

    Article  PubMed  Google Scholar 

  81. Saag KG. Bone safety of low-dose glucocorticoids in rheumatic diseases. Ann N Y Acad Sci. 2014;1318:55–64.

    Google Scholar 

  82. Lehman JS, Kalaaji AN. Role of primary prophylaxis for pneumocystis pneumonia in patients treated with systemic corticosteroids or other immunosuppressive agents for immune-mediated dermatologic conditions. J Am Acad Dermatol. 2010;63(5):815–23.

    Article  PubMed  Google Scholar 

  83. Brennan JG, Montgomery H. Pemphigus and other bullous dermatoses: correlation of clinical and pathologic findings. J Invest Dermatol. 1953;21(6):349–61; discussion 61–3.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology, The University of Iowa, 200 Hawkins Drive, Iowa City, IA, 52242, USA

    Megan H. Noe MD, MPH & Janet A. Fairley MD

Authors
  1. Megan H. Noe MD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Janet A. Fairley MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Janet A. Fairley MD .

Editor information

Editors and Affiliations

  1. Department of Dermatology, University of Alabama at Birmingham, BIRMINGHAM, Alabama, USA

    Naveed Sami

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Noe, M.H., Fairley, J.A. (2016). Bullous Pemphigoid. In: Sami, N. (eds) Autoimmune Bullous Diseases. Springer, Cham. https://doi.org/10.1007/978-3-319-26728-9_4

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-26728-9_4

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-26726-5

  • Online ISBN: 978-3-319-26728-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation